Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ensysce Biosciences (ENSC) Change in Accured Expenses (2020 - 2025)

Ensysce Biosciences (ENSC) has disclosed Change in Accured Expenses for 6 consecutive years, with $363308.0 as the latest value for Q3 2025.

  • On a quarterly basis, Change in Accured Expenses rose 77.01% to $363308.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $688120.0, a 38.44% decrease, with the full-year FY2024 number at $6198.0, down 66.76% from a year prior.
  • Change in Accured Expenses was $363308.0 for Q3 2025 at Ensysce Biosciences, up from $348842.0 in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $2.2 million in Q3 2021 to a low of -$987997.0 in Q2 2023.
  • A 5-year average of $156745.9 and a median of $27283.0 in 2024 define the central range for Change in Accured Expenses.
  • Biggest YoY gain for Change in Accured Expenses was 36644.04% in 2023; the steepest drop was 314.6% in 2023.
  • Ensysce Biosciences' Change in Accured Expenses stood at -$323228.0 in 2021, then skyrocketed by 100.91% to $2952.0 in 2022, then soared by 36644.04% to $1.1 million in 2023, then crashed by 102.49% to -$26977.0 in 2024, then skyrocketed by 1446.73% to $363308.0 in 2025.
  • Per Business Quant, the three most recent readings for ENSC's Change in Accured Expenses are $363308.0 (Q3 2025), $348842.0 (Q2 2025), and $2947.0 (Q1 2025).